Satellos Bioscience Inc (MSCLF)

[stocktrademan]

$ICOTF recent news/filings

bullish

## source: finance.yahoo.com

Tue, 19 Aug 2014 11:00:00 GMT ~ iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

[PR Newswire] - VANCOUVER, Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (ICO.V) (ICOTF), today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy. Memory cells, or white blood cells, from eight HIV-infected subjects with a durable viral suppression using antiretroviral therapy (HAART) were obtained and exposed in vitro to various concentrations of Oral Amp B. Samples from one patient were determined not to be susceptible to reactivation. In the remaining subjects, Oral Amp B demonstrated a reactivation response of HIV viral production in six out of seven in vitro cultures with detectable HIV reservoir. Some HIV reservoirs are not possible to reactivate and this may explain why one culture did not show reactivation response.

read full: http://finance.yahoo.com/news/ico-therapeutics-announces-positive-oral-110000218.html
*********************************************************

Tue, 19 Aug 2014 11:00:00 GMT ~ iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

[CNW Group] - iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

read full: http://finance.yahoo.com/news/ico-therapeutics-announces-positive-oral-110000134.html
*********************************************************

Tue, 19 Aug 2014 06:30:00 GMT ~ Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market

[PR Newswire] - CAMBRIDGE, Mass. and HERZLIYA-PITUACH, Israel, Aug. 19, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP"), a biotechnology company, today announced that it has received confirmation that its application to list its common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. IMMUNE's common stock is expected to begin trading on the NASDAQ Capital Market at the opening of trading on August 21, 2014 under the symbol IMNP. "We believe that trading on NASDAQ will enhance our visibility, increase our liquidity and provide access to a broader institutional investor base," said Dr. Daniel Teper, Chief Executive Officer of IMMUNE. "Uplisting to NASDAQ represents a significant milestone for IMMUNE as it gives us the opportunity to accelerate the development of Bertilimumab and other important drugs in our portfolio."

read full: http://finance.yahoo.com/news/immune-pharmaceuticals-announces-approval-listing-063000831.html
*********************************************************

Thu, 14 Aug 2014 06:30:00 GMT ~ Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials

[PR Newswire] - CAMBRIDGE, Mass. and HERZLIYA-PITUACH, Israel, Aug. 14, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP"), announced today its operating results for the quarter ended June 30, 2014. Dr. Daniel Teper, Chief Executive Officer of Immune Pharmaceuticals, Inc., stated: "Following the completion of a $10.2 million capital raise in March 2014, in the second quarter, we have been able to advance the preparation of Phase II clinical trials for Bertilimumab. As a result, both trials, in Bullous Pemphigoid, an Orphan Auto-Immune Disease of the skin, and in Ulcerative Colitis trial, are initiating patient screening in the third quarter."

read full: http://finance.yahoo.com/news/immune-pharmaceuticals-announces-second-quarter-063000804.html
*********************************************************

Wed, 30 Jul 2014 06:30:00 GMT ~ Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin

[PR Newswire] - "Immune" or "the Company") announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of moderate to severe bullous pemphigoid. This open-label trial will enroll 10-15 patients who will receive two bertilimumab infusions, at a dose of 10 mg/kg, on days 0 and 14. Patients will be followed for eight weeks with primary efficacy end points focused on disease control measured by the Bullous Pemphigoid Disease Area Index, a validated index developed by international experts in this indication, and steroid sparing, the proportion of patients who achieve a steroid dose of Dr. Daniel Teper, Chairman and CEO of Immune comments: "Following the announcement last week of our partnership with Lyfebulb, and future collaborative activities with the International Pemphigus and Pemphigoid Foundation (IPPF), we are pleased to announce the commencement of patient screening in a Phase II bullous pemphigoid clinical trial with bertilimumab.

read full: http://finance.yahoo.com/news/immune-pharmaceuticals-commences-patient-screening-063000318.html
*********************************************************


$ICOTF charts

basic chart ## source: stockcharts.com



basic chart ## source: eoddata.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ICOTF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ICOTF/company-info
Ticker: $ICOTF
OTC Market Place: OTCQX International
CIK code: 0001421642
Company name: Ico Therapeutics, Inc.
Company website: http://www.icotherapeutics.com/
Incorporated In: British Columbia, Canada

Business Description: iCo Therapeutics has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-2008 is targeted for the treatment of vernal or atopic keratojunctivitis and wet age-related macular degeneration.


$ICOTF share structure

## source: otcmarkets.com

Market Value: $5,827,582 a/o Aug 19, 2014
Shares Outstanding: 84,457,713 a/o May 29, 2014
Float: 62,821,290 a/o Nov 21, 2013
Authorized Shares: Unlimited a/o Nov 21, 2013
Par Value: No Par Value
$ICOTF extra dd links

Company name: Ico Therapeutics, Inc.
Company website: http://www.icotherapeutics.com/

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ICOTF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ICOTF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ICOTF+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ICOTF/news - http://finance.yahoo.com/q/h?s=ICOTF+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ICOTF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ICOTF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ICOTF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ICOTF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ico+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ico+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ico+Therapeutics%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.icotherapeutics.com/
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.icotherapeutics.com/#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.icotherapeutics.com/

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ICOTF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001421642&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ICOTF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ICOTF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ICOTF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ICOTF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ICOTF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ICOTF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ICOTF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ICOTF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ICOTF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ICOTF+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ICOTF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ICOTF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ICOTF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ICOTF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ICOTF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ICOTF/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ICOTF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ICOTF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ICOTF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ICOTF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ICOTF



$ICOTF DD Notes ~ http://www.ddnotesmaker.com/ICOTF